Search
Insulin glargine
go.drugbank.com/drugs/DB00047ApprovedInvestigationalAvailable as the brand name product Lantus, insulin glargine has a duration of action up to 24 hours allowing for once-daily dosing, typically at bedtime. … Insulin glargine is also available as the biosimilar, or "follow-on" product, Basaglar in the US and as Abasaglar in the EU.
Histrelin
go.drugbank.com/drugs/DB06788ApprovedInvestigationalWithdrawnHistrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. … As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007).[L41700]
Futibatinib
go.drugbank.com/drugs/DB15149ApprovedInvestigationalFGFR was investigated in oncology as a therapeutic target, as FGFR genomic aberrations and dysregulated FGFR signalling pathways are observed in some cancers such as cholangiocarcinoma and urothelial malignancies … [A253193,A253198] As a novel inhibitor of FGFR, futibatinib was first approved by the FDA in September 2022 to treat different types of intrahepatic cholangiocarcinoma.
Magnesium oxide
go.drugbank.com/drugs/DB01377ApprovedInvestigationalIt is used as an antacid and mild laxative and has many nonmedicinal uses. … Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide.
Vecuronium
go.drugbank.com/drugs/DB01339ApprovedInvestigationalIts lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or
Hydroxypropyl cellulose
go.drugbank.com/drugs/DB00840ApprovedAs a food additive, hydroxypropyl cellulose is used as a thickener and as an emulsion stabilizer. … used to treat syndromes characterized by insufficient tear production (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis, and as
Susoctocog alfa
go.drugbank.com/drugs/DB11606ApprovedInvestigationalSusoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for intravenous injection. … AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the activated partial thromboplastin time (aPTT) assay, a conventional in vitro test for biological activity of
Synonyms: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATEDMoxonidine
go.drugbank.com/drugs/DB09242ApprovedInvestigationalWithdrawnAs well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome. … It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive.
Products: MOXONIDINA MYLAN GENERICSPergolide
go.drugbank.com/drugs/DB01186ApprovedVet approvedWithdrawnThe drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. … It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy.
Products: PERGOLIDE MYLAN GENERICSSodium tartrate
go.drugbank.com/drugs/DB13707ApprovedWithdrawnIt is obtained as a byproduct of wine manufacturing. Sodium tartrate is generally recognized as safe (GRAS) as a direct human food ingredient. … It acts as an emulsifier and pH control agent in food products [L2590].